BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27343420)

  • 1. Prolonged utilization of proton pump inhibitors in patients with ischemic and valvular heart disease is associated with surgical treatments, weight loss and aggravates anemia.
    Boban M; Zulj M; Persic V; Medved I; Zekanovic D; Vcev A
    Int J Cardiol; 2016 Sep; 219():277-81. PubMed ID: 27343420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cardiovascular treatments and systolic dysfunction on nutritional risk in patients with ischemic and valvular heart disease.
    Boban M; Persic V; Petricevic M; Manola S; Boban L; Vcev A
    J Am Coll Nutr; 2015; 34(2):159-66. PubMed ID: 25751132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Connections between nutritional status and proton pump inhibitor therapy in patients scheduled for cardiovascular rehabilitation after treatment for ischaemic and valvular heart disease.
    Boban M; Persic V; Petricevic M; Biocina B; Sipic T; Pehar-Pejcnovic V; Balen S; Zulj M; Vcev A
    Kardiol Pol; 2016; 74(5):461-468. PubMed ID: 26412474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of proton pump inhibitors and risk of ischemic events in the general population.
    Casula M; Scotti L; Galimberti F; Mozzanica F; Tragni E; Corrao G; Catapano AL
    Atherosclerosis; 2018 Oct; 277():123-129. PubMed ID: 30212680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term proton pump inhibitor therapy on hemoglobin and serum iron levels after sleeve gastrectomy.
    Sharma N; Chau WY; Dobruskin L
    Surg Obes Relat Dis; 2019 Oct; 15(10):1682-1689. PubMed ID: 31422079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
    Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
    Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.
    Wang YF; Chen YT; Luo JC; Chen TJ; Wu JC; Wang SJ
    Am J Gastroenterol; 2017 Jul; 112(7):1084-1093. PubMed ID: 28397874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
    Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
    J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.
    Schmidt M; Johansen MB; Robertson DJ; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Sørensen HT; Baron JA
    Aliment Pharmacol Ther; 2012 Jan; 35(1):165-74. PubMed ID: 22050009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors and vascular function: A prospective cross-over pilot study.
    Ghebremariam YT; Cooke JP; Khan F; Thakker RN; Chang P; Shah NH; Nead KT; Leeper NJ
    Vasc Med; 2015 Aug; 20(4):309-16. PubMed ID: 25835348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?
    Mikolasevic I; Milic S; Stimac D; Zaputovic L; Lukenda Zanko V; Gulin T; Jakopcic I; Klaric D; Gulin M; Orlic L
    Eur J Intern Med; 2016 May; 30():99-103. PubMed ID: 26905320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting.
    Oudit GY; Bakal JA; McAlister FA; Ezekowitz JA
    Eur J Heart Fail; 2011 Nov; 13(11):1211-5. PubMed ID: 21831912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
    Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
    Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.
    de Jager CP; Wever PC; Gemen EF; van Oijen MG; van Gageldonk-Lafeber AB; Siersema PD; Kusters GC; Laheij RJ
    Aliment Pharmacol Ther; 2012 Nov; 36(10):941-9. PubMed ID: 23034135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients.
    Shikata T; Sasaki N; Ueda M; Kimura T; Itohara K; Sugahara M; Fukui M; Manabe E; Masuyama T; Tsujino T
    Circ J; 2015; 79(1):193-200. PubMed ID: 25392070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
    Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
    Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.
    Meli M; Raffa MP; Malta R; Morreale I; Aprea L; D'Alessandro N
    Int J Clin Pharm; 2015 Dec; 37(6):1152-61. PubMed ID: 26319396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.